1256 related articles for article (PubMed ID: 33155660)
41. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
Bai J; Gui S; Zhang Y
J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357
[TBL] [Abstract][Full Text] [Related]
42. Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells.
Miller M; Chen S; Woodliff J; Kansra S
Endocrinology; 2008 Aug; 149(8):4158-67. PubMed ID: 18450960
[TBL] [Abstract][Full Text] [Related]
43. Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas.
Geng X; Ma L; Li Z; Li Z; Li J; Li M; Wang Q; Chen Z; Sun Q
World Neurosurg; 2017 Apr; 100():407-416. PubMed ID: 28137551
[TBL] [Abstract][Full Text] [Related]
44. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
Arita K; Uozumi T; Ohta M
Endocrinol Jpn; 1988 Jun; 35(3):503-9. PubMed ID: 3197661
[TBL] [Abstract][Full Text] [Related]
45. The prolactin-release inhibitor paeoniflorin suppresses proliferation and induces apoptosis in prolactinoma cells via the mitochondria-dependent pathway.
Wei Y; Zhou X; Ren L; Wang C; Li Y
J Cell Biochem; 2018 Jul; 119(7):5704-5714. PubMed ID: 29388711
[TBL] [Abstract][Full Text] [Related]
46. Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
Missale C; Losa M; Boroni F; Giovanelli M; Balsari A; Spano PF
Br J Cancer; 1995 Dec; 72(6):1397-9. PubMed ID: 8519650
[TBL] [Abstract][Full Text] [Related]
47. Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1.
Guh JY; Huang JS; Chen HC; Hung WC; Lai YH; Chuang LY
Am J Kidney Dis; 2001 Nov; 38(5):1096-104. PubMed ID: 11684565
[TBL] [Abstract][Full Text] [Related]
48. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism.
Missale C; Losa M; Sigala S; Balsari A; Giovanelli M; Spano PF
Mol Endocrinol; 1996 Mar; 10(3):272-85. PubMed ID: 8833656
[TBL] [Abstract][Full Text] [Related]
49. Augmented Stat5 Signaling Bypasses Multiple Impediments to Lactogen-Mediated Proliferation in Human β-Cells.
Chen H; Kleinberger JW; Takane KK; Salim F; Fiaschi-Taesch N; Pappas K; Parsons R; Jiang J; Zhang Y; Liu H; Wang P; Bender AS; Frank SJ; Stewart AF
Diabetes; 2015 Nov; 64(11):3784-97. PubMed ID: 26159175
[TBL] [Abstract][Full Text] [Related]
50. Three-dimensional imaging of hormone-secreting cells and their microvessel environment in estrogen-induced prolactinoma of the rat pituitary gland by confocal laser scanning microscopy.
Itoh J; Kawai K; Serizawa A; Yamamoto Y; Ogawa K; Matsuno A; Watanabe K; Osamura RY
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):364-70. PubMed ID: 11759065
[TBL] [Abstract][Full Text] [Related]
51. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
52. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
[TBL] [Abstract][Full Text] [Related]
53. Novel indoloquinoline derivative, IQDMA, suppresses STAT5 phosphorylation and induces apoptosis in HL-60 cells.
Chien CM; Yang SH; Lin KL; Chen YL; Chang LS; Lin SR
Chem Biol Interact; 2008 Oct; 176(1):40-7. PubMed ID: 18638462
[TBL] [Abstract][Full Text] [Related]
54. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
55. Inhibiting MAPK14 showed anti-prolactinoma effect.
Ding QY; Zhang Y; Ma L; Chen YG; Wu JH; Zhang HF; Wang X
BMC Endocr Disord; 2020 Sep; 20(1):138. PubMed ID: 32894113
[TBL] [Abstract][Full Text] [Related]
56. ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
Zhu J; Tang C; Cong Z; Yuan F; Cai X; Yang J; Ma C
Endocr Relat Cancer; 2021 Dec; 29(2):33-46. PubMed ID: 34821219
[TBL] [Abstract][Full Text] [Related]
57. Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine.
Osamura RY; Watanabe K
Acta Pathol Jpn; 1986 Aug; 36(8):1131-7. PubMed ID: 3776530
[TBL] [Abstract][Full Text] [Related]
58. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
Lloyd HM; Jacobi JM; Willgoss DA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
[TBL] [Abstract][Full Text] [Related]
59. Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line.
Lv H; Li C; Gui S; Sun M; Li D; Zhang Y
J Neurooncol; 2011 Apr; 102(2):237-45. PubMed ID: 20700755
[TBL] [Abstract][Full Text] [Related]
60. IL-32γ suppresses lung cancer stem cell growth via inhibition of ITGAV-mediated STAT5 pathway.
Lee YS; Kim KC; Mongre RK; Kim JY; Kim YR; Choi DY; Song S; Yun J; Han SB; Yoon DY; Hong JT
Cell Death Dis; 2019 Jul; 10(7):506. PubMed ID: 31263095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
